CANC Fact Sheet: Tema Oncology ETF
Share
$37.52
close, Nov 20, 2026
Over the year to Nov 19, 2026, CANC returned +13.0% in total and charged 0.75% a year.
- 1-year total return
- +10.3%
- to Nov 20, 2026
- Expense ratio
- 0.75%
- a year
- Net assets
- $198m
- on Nov 19, 2026
- Net flow, last 5 trading days
- +$2.1m
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
CANC $11,296 +13.0% · VOO $11,147 +11.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−9.7%
3 months−15.9%
Year to date+8.1%
1 year+10.3%
3 years+69.8%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
GENMAB A/S6.47%
REVOLUTION MEDICINES INC5.54%
ELI LILLY & CO5.13%
COGENT BIOSCIENCES INC4.47%
BEONE MEDICINES LTD4.45%
MERCK & CO INC4.35%
EXELIXIS INC3.82%
CG ONCOLOGY INC3.76%
NOVARTIS AG3.74%
ABBVIE INC3.48%
CANC top ten by weight, 45.2% of the fund, of its 54 equity positions, from the holdings published by its issuer for Nov 19, 2026.
Facts
Holds 54 stocks in therapeutics and medical devices, 20% of its weight in S&P 500 companies · First traded Aug 15, 2023 · Benchmark Its own holdings, as of Nov 19, 2026